Cancercompass News: breast cancerCancerCompass is an online community committed to offering people living with cancer a place to receive cancer information and news, share knowledge, and share cancer treatment experiences. To learn more, visit our site today.First Taxane-Based Non-Anthracycline Containing Chemotherapy In Combination With Herceptin TCH For HER2 Positive Early Breast Cancer Patients Obtains- June 6, 2008 The Cancer International Research Group (CIRG), a division of TRIO (Translational Research in Oncology) announced that, based on its study BCIRG 006, the U.S. Food and Drug Administration (FDA) has approved a new treatment consisting of the chemotherapeutic agents Taxotere(R) (docetaxel) and carboplatin combined with Herceptin(R) (trastuzumab) (TCH) for the adjuvant (post-surgery) treatment of HER2 (Human Epidermal growth factor Receptor 2)-positive early breast cancer. The AC-TH regimen...http://www.cancercompass.com/cancer-news/1,14301,00.htm?rss=y MammaPrint Breast Cancer Test Provides Valuable Insight For Personalized Treatment Decisions- June 6, 2008 Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced that data from two studies involving its MammaPrint(R) breast cancer prognosis test will be presented at the American Society of Clinical Oncology's (ASCO) annual meeting. Collectively, these findings show that MammaPrint, a prognostic test for breast cancer recurrence using a 70-gene signature, provides important information for more effective patient management. "These studies demonstrate the clinical.http://www.cancercompass.com/cancer-news/1,14302,00.htm?rss=y Combination Therapy Of Solvent-free Abraxane And The Targeted Therapy Bevacizumab Evaluated As First-line Treatment For Metastatic Breast Cancer- June 3, 2008 CHICAGO -- Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in combination with bevacizumab for the first-line treatment of metastatic breast cancer. The preliminary analysis showed that ABRAXANE (ABI-007 or nab-paclitaxel).http://www.cancercompass.com/cancer-news/1,14271,00.htm?rss=y MammoSite 5-day Targeted Radiation Therapy- June 3, 2008 "Early detection is the best protection." It's been the mantra of breast cancer prevention messages for years. In fact the Center for Disease Control and Prevention reports that when breast cancer is discovered at an early, localized stage and treated, there is a 98 percent five-year survival rate. That's important because, according to the American Cancer Society, a woman in the United States has a one in eight chance of developing invasive breast cancer. Among the successful treatments for...http://www.cancercompass.com/cancer-news/1,14269,00.htm?rss=y New Genetic Test Aims To Improve Breast Cancer Treatment- June 3, 2008 Dr. Matthew Ellis stands at the dawn of personalized medicine, his work heralding a day when breast cancer patients will receive just the right treatment for their specific type of disease. Ellis, a researcher at Washington University School of Medicine and co-founder of St. Louis-based University Genomics Inc., is developing genetic tests for analyzing individual tumors. The tests could predict patients' responses to treatment options. Some would be spared the harsh side effects and cost of...http://www.cancercompass.com/cancer-news/1,14270,00.htm?rss=y |